BUTYRIC ACID AND INULIN IN THE COMBINATION TREATMENT OF ABDOMINAL PAIN IN IRRITABLE BOWEL SYNDROME


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The combination of trimebutine and Zacofalc has been shown to surpass that of trimebutine and lactobacteria in efficacy when comparing the magnitude of pain syndrome (p=0.04) and the intensity of painful sensations (p=0.042). The former combination is an effective agent for the therapeutic correction of abdominal pain in patients with irritable bowel syndrome.

全文:

受限制的访问

作者简介

A. Nizhevich

Bashkir State Medical University

Email: aanj@yandex.ru

E. Koroleva

OOO «Endomed», Gastrocenter Clinic

E. Astrelina

OOO «Endomed», Gastrocenter Clinic

V. Alyangin

Bashkir State Medical University; OOO «Endomed», Gastrocenter Clinic

参考

  1. Пиманов С.И., Силивончик Н.Н. Римский III консенсус: Избранные разделы и комментарии / Витебск: Издательство ВГМУ, 2006; 160 с.
  2. Шептулин А.А. Римские критерии III синдрома раздраженного кишечника: что мы ожидали и что мы увидели? // РЖГГК. - 2007; 2: 63-8.
  3. Rey E., Talley N. Irritable bowel syndrome: Novelviews on the epidemiology and potential risk factors // Dig. Liver Dis. - 2009; 41: 772-80.
  4. Gweek A., Wee S., Wong M. et al. The prevalence, symptom chаrаcteristics and impact of irritable bowel syndrome in an Asian urban community // Am. J. Gastroenterol. - 2004; 99: 924-31.
  5. Mangel A., Northcutt A. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients // Aliment. Pharmacol. Ther. - 1999; 13 (Suppl. 2): 77-82.
  6. Ghoshal U., Abraham P., Bhatt C. et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology task force // Indian J. Gastroenterol. - 2008; 27 (1): 22-8.
  7. Whitehead W., Crowell M., Davidoff A. et al. Pain from rectal distension in women with irritable bowel syndrome // Dig. Dis. Sci. - 1997; 42: 796-804.
  8. Whitehead W., Holtkotter B., Enck P. et al. Tolerance for rectosigmoid distension in irritable bowel syndrome // Gastroenterology. - 1990; 98: 1187-92.
  9. Ардатская М.Д. Масляная кислота и инулин в клинической практике: теоретические аспекты и возможности клинического применения / М.: Фортепринт, 2014; 64 c.
  10. Banasiewicz T., Kaczmarek E., Maik J. et al. Quality of life andthe clinical symptoms at the patients with irritable bowel syndrometreated complementary with protected sodium butyrate // Gastroenterol. Prakt. - 2011; 5: 45-53.
  11. Banasiewicz T., Kaczmarek E., Maik J. et al. The influence of protected sodium butyrate on frequency and severity some clinicalsymptoms at the patients with irritable bowel syndrome // Gastroenterol. Prakt. - 2012; 1: 16-23.
  12. Tarnowski W., Borycka-Kiciak K., Kiciak A. et al. Outcome oftreatment with butyric acid in irritable bowel syndrome - preliminaryreport // Gastroenterol. Prakt. - 2011; 1: 43-8.
  13. Vanhoutvin S., Troost F., Kilkens T. et al. The effects of butyrate enemas on visceral perception in healthy volunteers // Neurogastroenterol. Motil. - 2009; 21 (9): 952-76.
  14. Маев И.В., Кучерявый Ю.А., Черемушкин С.В. Эволюция представлений о синдроме разраженного кишечника. Методические рекомендации для врачей / М., 2013; 80 с.
  15. Васильев Ю.В. Синдром раздраженного кишечника: современные аспекты диагностики и терапии // Мед. Совет. - 2014; 4: 72-7.
  16. Nijevitch A., Akhmadeeva E., Sataev V. et al. Efficacy of Trimebutine Maleate in the Treatment of Functional Dyspepsia in Childhood // J. Nepal. Paediatr. Soc. - 2013; 33 (2): 158-62.
  17. Delvaux M., Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results // J. Int. Med. Res. - 1997; 25 (5): 225-46.
  18. Lee H., Kim B. Trimebutine as a modulator of gastrointestinal motility // Arch. Pharm. Res. - 2011; 34 (6): 861-4.
  19. Fioramonti J., Bueno L. Centrally acting agents and visceral sensitivity // Gut. - 2002; 51 (Suppl. 1): 91-5.
  20. Sarnelli G. Gut microbiota and irritable bowel syndrome: a further link between the big brain - little brain axis // J. Prob. Health. - 2014; 2 (2): 107.
  21. Lee K., Tack J. Altered intestinal microbiota in irritable bowel syndrome // Neurogastroenterol. Motil. - 2010; 22 (5): 493-8.
  22. Collins S., Denou E., Verdu E. et al. The putativerole of the intestinal microbiota in the irritable bowel syndrome // Dig. Liver Dis. - 2009; 41 (12): 850-3.
  23. Sudo N., Chida Y., Aiba Y. et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice // J. Physiol. - 2004; 558 (Pt. 1): 263-75.
  24. Kunze W., Mao Y., Wang B. et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening // J. Cell. Mol. Med. - 2009; 13 (8B): 2261-70.
  25. Salonen A., de Vos W., Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives // Microbiology. - 2010; 156 (Pt. 11): 3205-15.
  26. Topping D., Clifton P. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides // Physiol. Rev. - 2001; 81 (3): 1031-64.
  27. Załęski A., Banaszkiewicz A., Walkowiak J. Butyric acid in irritable bowel syndrome // Prz. Gastroenterol. - 2013; 8 (6): 350-3.
  28. Guilloteau P., Martin L., Eeckhaut V. et al. From the gut to the peripheral tissues: the multiple effects of butyrate // Nutr. Res. Rev. - 2010; 23 (2): 366-84.
  29. Ерофеев Н.П., Радченко В.Г., Селиверстов П.В. Клиническая физиология толстой кишки. Механизмы действия короткоцепочечных жирных кислот в норме и при патологии: монография / СПб: Форте Принт, 2012; 56 с.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2015
##common.cookie##